Xencor | XNCR - Interest Expense On Debt


Xencor reported $7.66M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Alnylam Pharmaceuticals USD 44.4M 4.15M Sep/2025
Amgen USD 653M 32M Dec/2025
Arrowhead Research USD 21.69M 2.69M Sep/2025
AstraZeneca USD 303M 38M Jun/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 480M 5M Sep/2025
Cytokinetics USD 26.32M 2.06M Sep/2025
GlaxoSmithKline GBP 167M 17M Sep/2025
J&J USD 18M 290M Sep/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Merck USD 412M 85M Dec/2025
Novartis USD 281M 8M Sep/2025
Pfizer USD 711M 59M Dec/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Xencor USD 7.66M 578K Sep/2025